After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
More information: Cara L. McDermott et al, Fall Risk and Medication Use Near End of Life Among Adults With Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Diseases ...
Centre, a national research platform led by Nanyang Technological University, Singapore’s (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...